Logo

Jazz Publishes Results of Xywav in P-III Study for the Treatment of Idiopathic Hypersomnia in Lancet Neurology

Share this

Jazz Publishes Results of Xywav in P-III Study for the Treatment of Idiopathic Hypersomnia in Lancet Neurology

Shots:

  • The P-III withdrawal study evaluate Xywav vs PBO in 154 adults aged 19 to 75yrs. with idiopathic hypersomnia at 50 centers in seven countries
  • The results showed a significant differences with Xywav compared to PBO in the 1EPs of change in ESS score and 2EPs showed an improvement in idiopathic hypersomnia symptoms including excessive daytime sleepiness, sleep inertia, prolonged sleep duration, and improved daytime performance. The safety profile was consistent with other oxybate studies
  • Xywav is a lower-sodium oxybate & the FDA-approved therapy for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7yrs. with narcolepsy & for idiopathic hypersomnia in adults

Ref: PR Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions